Important Definitions

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course . Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about (online CE course)
Important Definitions

Allogeneic transplant: Hematopoietic cells collected from an HLA-compatible sibling, family member, or unrelated donor
Apheresis: The removal of normal or abnormal cells or plasma from the blood.
Autologous transplant: A patient’s own hematopoietic cells, collected when the patient is in remission.
Graft versus host disease (GVHD): A reaction of immunocompetent T-cells from the donor that attack the recipient's skin, gut, liver, and hematopoietic cells.
Graft versus tumor effect: Transplanted T-cells attacking and killing cancer cells in the recipient.
CD34: The antigen found on uncommitted hematopoietic stem cells and early progenitor cells of the hematopoietic system.
Chimerism: The presence of donor cells in the peripheral blood and/or the bone marrow of the transplant recipient.
Donor lymphocyte infusion (DLI): A technique to prevent graft rejection.
Haplotype identical transplant: A transplant from a sibling or parent that matches 50% of the HLA genes of the patient.
Histocompatibility/human leukocyte antigens (HLA): Genetically determined antigens found on the surface of cell membranes that identify a cell as "self" or "non-self."
Minimal residual disease: The presence of neoplastic cells in the absence of clinical or morphologic evidence of disease.
Myeloablative therapy: Immunosuppressive therapy using chemotherapy and radiation therapy to reduce rejection of the HSC transplant.
Nonmyeloablative therapy: Suppression of graft versus host disease with increased graft versus tumor.